Temozolomide

This classification denotes a triazene compound and gonadotropin releasing hormone inhibitor with the molecular formula C6H6N6O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YF1K15M17Y, chemically known as 3,4-dihydro-3-methyl-4-oxoimidazo(5,1-d)-as-tetrazine-8-carboxamide but more generally known as temozolomide, which bears US NIH Compound Identifier 5394. European Medicines Agency schedules Temozolomide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10889MIG. The term TEMOZOLOMIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 1, No. 4, 1987, List 27). World Health Organization schedules temozolomide in its Anatomical Therapeutic Chemical (ATC) Classification. TEMOZOLOMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule temozolomide under HS 29339990 and SITC 51577. As of Q4 2014, TEMOZOLOMIDE remains US FDA's Preferred Term for this commodity. Temozolomide bears US NLM identifiers UMLS ID C0076080 and NCI Concept Code C1244. SMILES: O=C1N2C(NNN1C)C(NC2)C(=O)N.